WEP Clinical

Exhibitor

At WEP Clinical, we deliver end-to-end support from clinical strategy to pricing, reimbursement, integrated evidence generation plans, and early market access, tailored to your product portfolio.

Our experienced Market Access team delivers customised strategies to ensure global, sustainable access for both payers and patients. By integrating patient-centred outcomes, rigorous market analysis, and proactive stakeholder engagement, we drive successful market entry and long-term commercial value.

Our services include:

• Development of global value dossiers and objection-handling materials, with tailored localisation for priority markets
• Creation of HTA dossiers and robust HEOR models for key markets to support reimbursement and access
• In-depth country-level access landscape assessments, particularly for complex indications (e.g., rare diseases, oncology, and advanced therapies such as cell and gene therapies)
• Strategic launch sequencing and development of pricing corridors to optimise market entry and value realisation, including consideration of international reference pricing dynamics and evolving policies such as MFN
• Design and facilitation of payer advisory boards, alongside targeted KOL engagement to strengthen evidence and access strategies
• Early preparation for EU Joint Clinical Assessments (JCA), including robust PICO development to ensure alignment with HTA expectations and optimise evidence generation strategies

website